Payment overview · 2025
General Payments
$375.86
19 reported records · 11 companies
Healthcare provider profile · identity verified
Sailaja Datla, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAINT CLAIR SHORES, MI · NPI 1154434975
Verified facts
What the public records show
CMS Open Payments records show Sailaja Datla, MD received $375.86 in general payments during 2025 across 19 reported records.
Exact Sciences Corporation accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 240 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $83.61 | 22.2% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $55.02 | 14.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.33 | 11.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.27 | 11.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $39.67 | 10.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.98 | 8.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.72 | 4.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.04 | 4.5% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.78 | 4.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.32 | 4.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.12 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $375.86 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $83.61 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $55.02 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $44.33 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $44.33 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $39.67 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.98 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.98 | 2 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 45 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 107 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 240 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
47 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
240 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
107 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
168 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 671 | 157 |
| Amlodipine Besylate | Amlodipine Besylate | 538 | 137 |
| Levothyroxine Sodium | Levothyroxine Sodium | 396 | 80 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 389 | 57 |
| Furosemide | Furosemide | 367 | 94 |
| Losartan Potassium | Losartan Potassium | 351 | 81 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 347 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 313 | 65 |
| Omeprazole | Omeprazole | 313 | 60 |
| Carvedilol | Carvedilol | 262 | 60 |
| Lisinopril | Lisinopril | 254 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 247 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 245 | 57 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 240 | 39 |
| Diclofenac Sodium | Diclofenac Sodium | 239 | 49 |
| Potassium Chloride | Potassium Chloride | 237 | 50 |
| Alprazolam | Alprazolam | 228 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 216 | 51 |
| Metformin Hcl | Metformin Hcl | 216 | 54 |
| Famotidine | Famotidine | 207 | 43 |
| Gabapentin | Gabapentin | 206 | 42 |
| Oxycodone Hcl | Oxycodone Hcl | 173 | 17 |
| Eliquis | Apixaban | 168 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 166 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 150 | 38 |
| Simvastatin | Simvastatin | 144 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 142 | 15 |
| Xarelto | Rivaroxaban | 138 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 120 | 27 |
| Trazodone Hcl | Trazodone Hcl | 120 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 119 | 30 |
| Naloxone Hcl | Naloxone Hcl | 118 | 38 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 113 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 110 | 26 |
| Spironolactone | Spironolactone | 109 | 28 |
| Ozempic | Semaglutide | 107 | 15 |
| Sertraline Hcl | Sertraline Hcl | 101 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 100 | 27 |
| Ibuprofen | Ibuprofen | 97 | 28 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 94 | 17 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 94 | 26 |
| Donepezil Hcl | Donepezil Hcl | 94 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 13 |
| Allopurinol | Allopurinol | 90 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 87 | 23 |
| Nifedipine Er | Nifedipine | 79 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 75 | 20 |
| Tramadol Hcl | Tramadol Hcl | 75 | 18 |
| Januvia | Sitagliptin Phosphate | 72 | 14 |
| Jardiance | Empagliflozin | 70 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 70 | 16 |
| Levetiracetam | Levetiracetam | 68 | 15 |
| Novolog Flexpen | Insulin Aspart | 68 | 13 |
| Memantine Hcl | Memantine Hcl | 65 | 20 |
| Ibandronate Sodium | Ibandronate Sodium | 64 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 64 | 19 |
| Azithromycin | Azithromycin | 63 | 49 |
| Risperidone | Risperidone | 61 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 40 |
| Glipizide Er | Glipizide | 60 | 13 |
| Mirtazapine | Mirtazapine | 60 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 12 |
| Nystatin | Nystatin | 58 | 26 |
| Diazepam | Diazepam | 56 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 54 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 52 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 50 | 12 |
| Hydrocortisone | Hydrocortisone | 48 | 18 |
| Meloxicam | Meloxicam | 48 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 47 | 35 |
| Linzess | Linaclotide | 45 | 11 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 44 | suppressed |
| Nitroglycerin | Nitroglycerin | 43 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 43 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 43 | suppressed |
| Amoxicillin | Amoxicillin | 42 | 28 |
| Enalapril Maleate | Enalapril Maleate | 42 | 11 |
| Alcohol Pads | Alcohol Antiseptic Pads | 41 | suppressed |
| Atenolol | Atenolol | 41 | 11 |
| Pregabalin | Pregabalin | 41 | suppressed |
| Entresto | Sacubitril/Valsartan | 40 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 40 | suppressed |
| Naproxen | Naproxen | 40 | suppressed |
| Prednisone | Prednisone | 40 | 22 |
| Ammonium Lactate | Ammonium Lactate | 39 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Baclofen | Baclofen | 37 | suppressed |
| Glipizide | Glipizide | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Loperamide | Loperamide Hcl | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Nateglinide | Nateglinide | 34 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Lidocaine | Lidocaine | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Clonidine | Clonidine | 31 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 23 |
| Meclizine Hcl | Meclizine Hcl | 30 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | suppressed |
| Ranolazine Er | Ranolazine | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Rivastigmine | Rivastigmine | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Cilostazol | Cilostazol | 26 | suppressed |
| Colchicine | Colchicine | 26 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Calcitriol | Calcitriol | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 24 | suppressed |
| Nystop | Nystatin | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 19 |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 14 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Methimazole | Methimazole | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Fluvastatin Er | Fluvastatin Sodium | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 12 | suppressed |
| Ofloxacin | Ofloxacin | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $375.86 · 19 records | Exact Sciences Corporation | ABRYSVO, AIRSUPRA, COMIRNATY, Cologuard Collection Kit, Korlym, LINZESS, MOUNJARO, OTEZLA, Ozempic, PADCEV, PREVNAR 20, REPATHA, Rybelsus, TRELEGY ELLIPTA, XIFAXAN, ZENPEP | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error